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Abstract 
Objectives: Clinical practice guidelines represent a key tool to improve quality 
and reduce variability of cancer care. In 2004, Italian Association of Medical 
Oncology (AIOM) launched the RIGHT (Research for the Identification of the 
most effective and hIGHly accepted clinical guidelines for cancer Treatment) 
program. The third step, RIGHT3, evaluated the concordance between AIOM 
lung cancer guidelines and Italian clinical practice. 
Materials and methods: RIGHT3 was a retrospective observational study, 
conducted in 53 Italian centers treating lung cancer. Sampling from AIOM 
database of 230 centers was stratified by presence of thoracic surgery and 
geographic distribution. To describe the adherence to AIOM guidelines (2009 
edition), 11 indicators regarding diagnostic and treatment procedures were 
identified. Patients with non-small-cell lung cancer (NSCLC) diagnosis who had 
first visit in 2010 were divided into 3 groups, based on TNM stage: I-II-IIIA (5 
indicators), IIIB (3 indicators) and IV (3 indicators).  
Results: 708 patients were enrolled; 680 were eligible: 225 patients in stage I-II-
IIIA; 156 patients in stage IIIB; 299 patients in stage IV. Cyto-histological 
diagnosis was available in 96%, 97%, 96% of stage I-II-IIIA, IIIB, IV respectively. 
Positron-emission tomography was performed in 64% of stage I-II-IIIA and 46% 
of stage IIIB. 88% of stage I-II patients eligible for surgery underwent lobectomy; 
after surgery, 61% of stage II and 57% of stage IIIA patients received adjuvant 
chemotherapy. Among stage IIIB patients who received combined chemo-
radiotherapy, sequential approach was more common than concomitant 
treatment (86% vs. 14%). Among stage IV patients, 87% received platinum-
based first-line treatment, and 70% received second-line.  
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Conclusion: The RIGHT3 study showed that, in 2010, adherence to Italian 
NSCLC guidelines was high for many indicators (including those related to 
treatment of stage IV patients), but lower for some diagnostic procedures. 
Guidelines adherence monitoring can be useful to reduce variability in cancer 
care. 
 
Keywords: lung cancer; guidelines; treatment; diagnosis  
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1. Introduction 
In oncology as well as in other medical specialties, clinical practice guidelines 
are developed and regularly updated by several national and international health 
bodies and scientific societies, like the American Society of Clinical Oncology 
(ASCO) [1-2] and the European Society of Medical Oncology (ESMO) [3-4]. In 
2002, following the recommendations of the Italian National Institute of Health 
(Istituto Superiore di Sanità), the Italian Association of Medical Oncology 
(Associazione Italiana di Oncologia Medica, AIOM) established a working group 
with the aim of developing clinical practice guidelines for cancer treatment. 
These guidelines were first released in 2002, and thereafter have been annually 
updated: the most recent update has been released in October 2014, and the 
next is expected in October 2015. Several factors can influence both the 
acceptance and the correct use of guidelines: among the most relevant factors, 
the experience and motivation of physicians, the willingness of patients and the 
availability of resources [5]. 
The RIGHT (Research for the Identification of the most effective and hIGHly 
accepted clinical guidelines for cancer Treatment) project was designed in 2004, 
with the aim of evaluating how AIOM guidelines are applied in Italian clinical 
practice. In the RIGHT-1 study, the feasibility and the appropriateness of some 
indicators were assessed in a limited sample of breast cancer patients, recruited 
by few selected Institutions [6]. Subsequently, the survey was extended 
(RIGHT-2 study) and conducted on a higher number of patients with stage I or II 
invasive breast cancer or stage III colorectal cancer, treated in a large sample of 
oncology sites throughout Italy [7].  
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Subsequently, the third step of the RIGHT project (RIGHT-3) was focused on 
lung cancer. Similarly to other Western countries, lung cancer is the leading 
cause of tumor-related deaths in Italy [8]. According to a classification commonly 
used in recent decades, four main histotypes of lung cancer are 
adenocarcinoma (AC), squamous cell carcinoma (SCC), large-cell lung 
carcinoma (LCLC) and small cell lung cancer (SCLC). SCC, AC and LCLC have 
been traditionally grouped together as non-small cell lung cancer (NSCLC), due 
to similar therapeutic approaches, pathological and biological characteristics 
and prognosis. The RIGHT-3 study was limited to NSCLC patients, that 
currently represent about 85% of lung cancers. 
In this paper, we report the main results of the RIGHT-3 study, which aimed to 
evaluate the adherence to AIOM lung cancer guidelines in a large sample of 
Italian NSCLC patients, , describing the variability of cancer care in this setting. 
The project was based on the description of adherence to 2009 version of AIOM 
lung cancer guidelines [9] in the clinical management of patients who received 
their first visit during 2010. Therefore, the interpretation of the results presented 
in this paper should take into account that data are referred to that time window. 
For instance, the indicator of adherence about first-line treatment of advanced 
disease was the use of platinum-based chemotherapy, and no indicators about 
molecular characterization and use of targeted agents were used in this project. 
in fact, gefitinib has been reimbursed in Italy as first-line treatment for advanced 
NSCLC with Epidermal Growth Factor receptor mutation since May 2011, that is 
after the period considered in this study. As a general rule, the indicators of 
adherence to guidelines used in this project were chosen to describe the degree 
6 
 
of  variability in both the diagnostic setting and in the multidisciplinary treatment 
approach.   
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2. Patients and methods 
The RIGHT-3 study Steering Committee and members of the AIOM Lung 
Cancer Guidelines Working Group (see Appendix I) designed the study and 
defined the methods for data collection.  
RIGHT-3 was designed as a retrospective observational study, involving a 
representative sample of AIOM oncology clinical centres across Italy.  
A pilot phase confirmed the study feasibility, i.e. the availability of cases and of 
clinical data. Afterwards, the RIGHT-3 extended phase (hereafter named 
RIGHT-3 study) was conducted in order to evaluate the agreement between 
clinical practice and AIOM lung cancer guidelines. As specified in the 
Introduction, these guidelines are updated every year, and the reference version 
that was in force when the RIGHT-3 study was conducted was the 2009 version 
[9].  
The involved centers were randomly selected, to be a representative sample of 
the 230 oncology centers included in the national list identified in 2010 by AIOM. 
For this purpose, a two-stage sampling was performed: in the first stage, 
sampling unit were centers; in the second stage, sampling unit were patients. 
Based on the consideration that the patients with I-II-IIIA stage carcinoma are 
usually treated at centres with thoracic surgery unit (TU), while more advanced 
stages (IIIB, IV) patients management do not necessary need a TU, during the 
first stage of sampling, sites were randomly collected using a stratified sampling 
method, where strata were identified by geographic area (Northern, Central and 
Southern Italy, the latter including Sicily and Sardinia) and availability of TU 
(with / without TU).  
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Among centers without TU, ten Institutions were included in the sample without 
random selection: these units were identified according to the volume of patients 
managed (at least 50 patients NSCLC / year) and the  commitment in lung 
cancer patients care. The other 16 centers were randomly selected among the 
remaining centers without TU.  
During the second stage, patients were consecutively enrolled from November 
2011 until February 2012 with the following inclusion criteria: 1) first visit at 
oncology center between January and December 2010, in order to exclude 
patients managed by study centre before AIOM guidelines (2009 edition) 
entered into force; 2) age ≥18 years, without upper age limit; 3) diagnosis of 
NSCLC with TNM staging I-II-IIIA, IIIB or IV (patients with small cell lung cancer 
were excluded, and staging was considered mandatory because it is crucial for 
the proper evaluation of AIOM lung cancer guidelines stage-specific 
recommendations); 4) follow-up by the study center for at least 6 months after 
diagnosis to assure the availability of patient’s relevant information about clinical 
history and disease management; the patients who died during the 6 months 
after diagnosis were included in the analysis and the data available until death 
were collected and analysed. Patients who did not meet the four inclusion 
criteria listed above were excluded from the analysis. 
In order to avoid biases related to the availability of surgical facilities at each 
participating institution, centers with TU were asked to enrol patients in all 
stages, while centers without TU were asked to enrol patients in stages IIIB or 
IV.  
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To evaluate the adherence to AIOM lung cancer guidelines, three target 
populations were considered: patients with (i) stage I-II-IIIA, (ii) stage IIIB, (iii) 
stage IV NSCLC according to pathological (or, if not available, clinical) TNM 
staging system [10] assessed by the clinical investigators who participated in the 
study, at the moment they took on responsibility of the patient.  
To verify the agreement between guidelines and clinical practice, eleven 
indicators (five evaluated on stage I-II-IIIA, three on stage IIIB and three on 
stage IV patients) were identified by the AIOM Lung Cancer Guidelines Working 
Group. In Table 1, these 11 process indicators of lung cancer diagnosis and 
treatment are reported, along with a synthesis of recommendations included in 
the 2009 AIOM guidelines for each of the indicators. To minimize the response 
bias, in addition to random selection of centres and retrospective data collection, 
the participating centres were not aware of the indicators that had been chosen 
to assess compliance with guidelines. In order to describe the reasons of non-
adherence, each indicator was accompanied by a multiple choice questionnaire, 
to reveal any reasons for lack of implementation among the following: patient 
refusal, organizational or technical difficulties, clinician’s choice, patient’s clinical 
conditions or other reasons.  
The study was approved by the local Ethics Committees of each participating 
Institution; signed written informed consent was obtained from patients who 
were still alive during data collection. As for dead patients, Italian Privacy 
governance gave permission for treating their data without a written informed 
consent.  
Data collection was performed using a web-based interface (each center 
received a username and a password to access the electronic case report form). 
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The following data fields were recorded: 1) clinical and socio-demographic 
characteristics, 2) cancer-related variables such as stage, diagnosis and 
treatment, 3) care indicators. Onsite monitoring visits were performed in a 
sample of 13 centers, in order to ensure a proper data source verification of 
imputed data versus medical charts.  
2.1. Sample size and Statistical analysis 
The pilot phase was conducted on a convenience sample of 5 AIOM centers, 4 
with TU (one in Northern, two in Central and one in Southern Italy) and 1 without 
TU (located in Northern Italy). In this pilot phase, 22 patients (4 stage I-II-IIIA, 9 
stage IIIB and 9 stage IV) were considered. 
For the RIGHT-3 study, the number of centers needed for the study, set to 25 
with TU and 25 without TU, was defined on the basis of feasibility criteria.  In 
fact, according to the volume of patients managed by the centers involved, it 
was reasonable to suppose the inclusion of a number of NSCLC patients high 
enough to allow precise estimates of the outcome of interest, i.e. the proportion 
of patients adequately treated according to corresponding AIOM lung cancer 
guidelines.  
More in detail, the sample size was planned in order to have an absolute error 
(i.e. half-width of 95% confidence interval) of 10% at most. Because literature 
data about adherence to lung cancer guidelines were absent, the results of 
RIGTH-2 study on adherence to breast and colon-rectal cancer AIOM guidelines 
were considered. In particular, with a conservative point of view, colorectal 
cancer guidelines results were considered, because they showed a lower 
adherence if compared to breast cancer ones. In detail, colorectal cancer 
guidelines were correctly applied on average in 65% of enrolled patients. 
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Considering a design effect equal to 2, a percentage of not evaluable patients of 
15% and without considering finite population correction, the enrolment of 200 
patients for each of the three groups (I-II-IIIA, IIIB, IV stage) was planned. Of 
course, precision of the estimates would have been lower in the case of a 
smaller number of patients included: for instance, with half of planned sample 
size, absolute error would have been higher than 14%. 
The main outcome measure was the proportion of patients following 
recommended guidelines, for each of the 11 indicators. To avoid a possible 
underestimation of agreement percentage, as denominator of each indicator 
only the “eligible patients” were considered, i.e., the subgroup of patients for 
whom application of the recommended procedures was assessable and had no 
explicit contraindications. The average percentage of agreement for indicators 
was also calculated within each of three group of patients (I-II-IIIA, IIIB, IV stage) 
as the ratio between the number of patients who had been treated according to 
guidelines and the total number of eligible patients for all indicators.  
Absolute and relative frequencies were calculated for qualitative data; 
continuous normally distributed variables were expressed as a mean ± SD. Data 
were analysed using SAS for Windows, release 9.2 (SAS Institute Inc). Project 
management including data banking, quality control and statistical analysis, was 
performed by MEDIDATA (Modena, Italy).  
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3. Results 
Overall, 53 oncology clinical centers across Italy, 27 with TU and 26 without TU, 
were involved in the study (47% located in Northern Italy, 25% in Central Italy 
and 28% in Southern Italy). With respect to the 50 planned centers, the number 
of centers was intentionally slightly increased, in order to reach the target 
sample size. 
 
       3.1. Stage I-II-IIIA patients 
The case records of 233 patients in stage I-II-IIIA were examined and 225 (97%) 
of them were eligible for the analysis. Among the 8 patients excluded from the 
analysis, 2 had their first visit to the oncology center outside the eligible period, 
3 were not in stage I-II-IIIA and 3 had not a diagnosis of NSCLC. Table 2 
summarizes the main baseline socio-demographic and clinical features of these 
patients. Figure 1 shows the distribution of histology at diagnosis by stage. 
Cyto-histological diagnosis was available in 96% of patients; histotype was 
NSCLC not otherwise specified in 5% of cases. 
3.1.1. Diagnostic procedures 
Among non-invasive diagnostic procedures, the more frequently performed were 
chest computed tomography (87% of evaluable patients) and positron-emission 
tomography (PET) (64%); among the invasive procedures, the more frequent 
was fibro-bronchoscopy (42% of evaluable patients) (see Table 3 for details). 
Eight patients underwent both PET and mediastinoscopy, six of whom were N1-
N2 and two were N0 at diagnosis according to TNM classification [9].  
In Table 1, the number of eligible patients and the adherence for each lung 
cancer process indicator are reported. Only 3 patients (2% of stage I-II-IIIA 
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patients eligible for surgery) underwent exploratory thoracotomy: for this 
indicator, the adherence was 98%. The more frequent reasons for lack of 
implementation of diagnosis-related process indicators was clinician’s choice 
(85% and 84% of patients without PET and without mediastinoscopy 
respectively). 
3.1.2. Treatment 
Ninety-five per cent of the 153 patients eligible for surgery underwent surgical 
intervention with little differences among stages (99%, 95% and 88% of stage I, 
II and IIIA patients, respectively). The lack of surgical intervention was mainly 
due to patients’ conditions (7 out of 8 patients who did not undergo surgery). As 
detailed in Table 1, among the 110 stage I-II operable evaluable patients, 88% 
underwent lobectomy (81% lobectomy and 7% bi-lobectomy); lobectomy 
(including bi-lobectomy) was performed on 93% and 81% of stage I and II 
patients, respectively. Proportion of patients receiving lobectomy / bilobectomy 
was 77.5% / 8.8% respectively in younger patients, and 90.0% / 3.3% 
respectively in elderly patients. 
Ninety-nine stage II or IIIA patients underwent surgical intervention (in detail 46 
stage II and 53 stage IIIA); 59% of them subsequently received adjuvant 
chemotherapy (61% and 57% of stage II and IIIA, respectively). Patients did not 
undergo adjuvant chemotherapy for the following reasons: patient’s clinical 
conditions (43% of patients with available reason), negative lymph nodes (17%), 
clinician’s choice (13%), patient refusal (10%) or other reasons (a combination 
of the above mentioned). Proportion of patients receiving adjuvant 
chemotherapy was 67.1% and 34.6% among younger and elderly patients, 
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respectively. Patient’s general conditions were the most common reason for the 
exclusion of elderly patients.  
3.2. Stage IIIB patients 
The case records of 169 stage IIIB lung cancer patients were examined, and 
156 (92%) of these were eligible for the analysis. Among the 13 patients 
excluded from the analysis, 1 had the first visit to the oncology centre outside 
the period January-December 2010, 1 was not followed-up by the study center 
for at least 6 months after diagnosis, 12 were not stage IIIB (the same patient 
could have more than one violations). In Table 2, main baseline socio-
demographic and clinical features of the eligible patients are shown. Cyto-
histological diagnosis was available in 97% of patients; histotype was NSCLC 
not otherwise specified in 13% of cases.  
3.2.1. Diagnostic procedures 
Among non-invasive diagnostic procedures, the more frequently performed were 
chest computed tomography (87% of evaluable patients) and PET (46%); 
among the invasive procedures, the more frequent was fibro-bronchoscopy 
(51% of evaluable patients) (see Table 3 for details). Considering the sixty-
seven patients who did not undergo PET with explicit reason for non-execution, 
the more frequently provided motivation was clinician’s choice, alone (78%) or 
combined with other reasons, such as patient’s refusal or technical difficulties 
(7%).  
3.2.2. Treatment 
Sixteen patients (11% of evaluable ones) underwent surgical intervention, 75% 
of whom after mediastinoscopy or PET. Ninety-four per cent of evaluable 
patients received a first, second or third line chemotherapy treatment. As 
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depicted in Figure 2, the more frequent first-line treatment was chemotherapy 
alone (64% of evaluable patients) or in  combination with radiotherapy (28%) or 
targeted therapy (1%). Considering patients with a chemo-radiotherapy first-line 
treatment, 14% and 86% of them underwent a concurrent and sequential 
therapy, respectively (Table 1). Sequential treatment was much more common 
than concurrent approach, independently of age (88.0% and 83.3% in younger 
and elderly patients, respectively).  
One-hundred forty-six patients had a first-line chemotherapy or targeted 
therapy: 79% received a combination chemotherapy, 15% a single-agent 
chemotherapy and 6% a targeted therapy (with or without chemotherapy 
agents). Details of the first-line chemotherapy and targeted therapy are reported 
in Table 4.  
 
3.3. Stage IV patients 
The case records of 306 stage IV lung cancer patients were examined, and 299 
(98%) of them were eligible for the analysis. Among the 7 patients excluded 
from the analysis, 4 had the first visit to the oncology center outside the period 
January-December 2010, 1 was not followed-up by the study center for at least 
6 months after diagnosis, 1 was not stage IV  and 1 had not a NSCLC diagnosis 
In Table 2, main baseline socio-demographic and clinical features of the 299 
patients are reported. Cyto-histological diagnosis was available in 96% of cases; 
histotype was NSCLC not otherwise specified in 13% of patients.  
3.3.1. Diagnostic procedures 
Among non-invasive diagnostic procedures, the more frequently performed were 
chest computed tomography (91% of evaluable patients) and PET (44%); 
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among the invasive procedures, the more frequent was fibro-bronchoscopy 
(41% of evaluable patients) (see Table 3 for details).  
3.3.2. Treatment 
The more frequent first-line treatment was chemotherapy alone (72% of 
evaluable patients) or in association with radiotherapy (15%) or targeted therapy 
(3%) (see Figure 2). All lung cancer process indicators selected for stage IV 
patients were about therapy (see Table 1): more in detail, 87% of first-line 
chemotherapy treated patients had a platinum-based regimen treatment and 
70% of patients treated with first-line chemotherapy received a second-line 
treatment. Two-hundred seventy-six patients had a first-line chemotherapy or 
targeted therapy, 70% of whom had a combination chemotherapy, 14% a single-
agent chemotherapy and 15% a targeted therapy (with or without chemotherapy 
agents). Details of the first-line chemotherapy and targeted therapy 
administered are reported in Table 4. Considering the 90 patients older than 70 
years, 94% of them were treated with chemotherapy (irrespective of the line), 
while the proportion of younger patients treated with chemotherapy ranged 
between 100% for patients aged 30-40 and 40-50 years to 95% for patients 60-
70 years old.  
 
3.4. Summary of adherence  
Globally, on average, 67%, 39% and 81% of stage I-II-IIIA, IIIB and IV 
patients respectively received recommended care according to the lung cancer 
indicators chosen for the study; the higher adherence was observed for the 
proportion of stage I-II-IIIA patients who did not undergo exploratory 
thoracotomy (98%) and for the proportion of stage IV patients older than 70 
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years who underwent chemotherapy (94%). On the other hand, the lower 
adherence was observed for the proportion of stage III patients eligible for 
surhery  who underwent mediastinoscopy (7%).  
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4. Discussion 
In principle, the successful implementation of clinical practice guidelines should 
lead to an improvement in quality of health care, by decreasing inappropriate 
heterogeneity among different Institutions and different physicians, and 
expediting the application of effective improvements to clinical practice [5, 11]. 
Previous phases of the RIGHT project had described the adherence to clinical 
practice guidelines issued by Italian Association of Medical Oncology (AIOM) in 
breast cancer and colorectal cancer patients [6,7]. In the present analysis, we 
reported the evaluation of the adherence to specific AIOM clinical practice 
guidelines in a large sample of Italian patients affected by NSCLC. 
In the group of stage II and III patients who underwent surgery, proportion of 
subjects who subsequently received adjuvant chemotherapy in our analysis was 
59%. This proportion appears reasonable, considering that the most common 
reason for exclusion of patients from administration of adjuvant treatment, as 
declared by physicians, was their unfit clinical condition. After the publication of 
pivotal trials showing the efficacy of adjuvant chemotherapy, its penetration in 
daily clinical practice has significantly increased, although necessarily limited to 
a selected proportion of patients [12,13]. A previous survey conducted in 2009 
among Italian oncologists about the use of adjuvant treatment for NSCLC 
patients showed that, in principle, the majority of physicians considered the 
indication for adjuvant chemotherapy in clinical practice [14]. However, given the 
tolerability profile of platinum-based treatment, many patients could be judged 
unfit for treatment in clinical practice, due to age, clinical conditions, post-
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operative length of hospital stay, comorbidities [15]. Our data confirm this 
limitation. 
In the subgroup of stage IIIB patients studied in our analysis, the vast 
majority of subjects did not receive a  concurrent chemo-radiotherapy treatment, 
and were treated with a sequential approach. According to literature, use of 
concurrent  chemo-radiotherapy, as compared with sequential approach, is 
associated with improved survival, at the cost of increased acute esophageal 
toxicity [16]. The choice of a less toxic approach could justify, at least in part, the 
low use of concomitant treatment in Italian clinical practice. Furthermore, in 
some cases, radiotherapy could be delayed due to logistic reasons, or due to a 
specific medical decision, with the intention of obtaining a tumor shrinkage with 
chemotherapy before administering radiation therapy. In a survey conducted in 
2009 by the Italian Society of Radiation Oncology Lung Cancer Study Group 
among all Italian radiation oncology institutions, upfront concomitant radio-
chemotherapy was used in only 14% of cases, that is very similar to the 
proportion reported in the present analysis. Notably, in that survey, 53% of the 
institution declared that patients have a clinical examination by a radiation 
oncologist only after the beginning of chemotherapy, having already received 2-
4 cycles of chemotherapy in 82% of cases [17].  
In the subgroup of patients with advanced disease, adherence to guidelines, 
at least for the indicators chosen in this study, was high. Notably, the vast 
majority of elderly patients received chemotherapy, confirming that age itself is 
no more considered a barrier to receive active anti-cancer treatment. This is 
reassuring and coherent with the fact that important randomized trials, 
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demonstrating the feasibility and the efficacy of chemotherapy in elderly patients 
with advanced NSCLC, were conducted in Italy in the last decades [18,19]. 
 
5. Conclusions  
In conclusion, the RIGHT-3 project showed an encouraging application of 
guidelines in Italian clinical practice for patients with NSCLC, for most of the 
indicators, with some relevant exceptions, like the low diffusion of 
mediastinoscopy in the diagnostic phase of stage III operable patients and the 
very low application of  concurrent chemo-radiotherapy for locally advanced 
disease. Some of these exceptions deserve a specific comment: the use of 
mediastinoscopy, for example, has experienced a “physiological” reduction in 
recent years, due to the increasing diffusion of minimally invasive 
endosonography procedures (transesophageal and endobronchial ultrasound) 
that allow avoiding further procedures when nodal metastases are found at 
endosonography [20]. 
In principle, there can be many reasons for sub-optimal adherence to 
guidelines in clinical practice [21]. With the production and the periodical, regular 
update of guidelines, that are freely available on the association website, AIOM 
has the objective of reducing the barriers related to guidelines awareness and 
knowledge in Italy. Furthermore, this kind of analysis is useful to describe and 
understand the other potential barriers for an optimal application of guidelines in 
daily practice (for instance related to external factors, logistical issues or lack of 
resources), with the aim of further improving quality and homogeneity of 
patients’ management.  
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1. Appendix I: The RIGHT-3 study group  
Member of the AIOM guidelines Working Group 
• Sandro Barni, Ospedale Treviglio-Caravaggio, Bergamo 
• Evaristo Maiello, IRCCS Casa Sollievo della Sofferenza, San Giovanni 
Rotondo, Foggia 
 
Scientific secretary of the AIOM Lung Cancer guidelines  
• Massimo Di Maio, Dipartimento di Oncologia, Università di Torino, AOU San 
Luigi Gonzaga, Orbassano (TO) 
 
Steering Committee:  
• Lucio Crinò, Azienda Ospedaliera Perugia, Perugia 
• Andrea Ardizzoni, Azienda Ospedaliero-Universitaria di Parma, Parma 
• Federico Cappuzzo, Ospedale di Livorno,  Livorno 
• Ernesto Maranzano, Azienda Ospedaliera Santa Maria di Terni,  Terni 
• Silvia Novello, Dipartimento di Oncologia, Università di Torino, AOU San 
Luigi Gonzaga, Orbassano (TO) 
 
Participating centres:  
• Oncologia Medica Ospedale Treviglio-Caravaggio, Treviglio (Bergamo): 
Sandro Barni, Fausto Petrelli 
• U.O. Oncologia A.O.U. Arcispedale Sant'Anna, Ferrara: Elena Raisi, Antonio 
Frassoldati, Alessandra Santini, Patrizia Longo  
• Oncologia Ospedale S. Spirito, Casale Monferrato (Alessandria): Mario 
Botta, Maria Vittoria Oletti, Gabriele Biaggi, Alberto Muzio, Elisabetta Gattoni, 
Lorena Giaretto, Emiliana Bertoldo 
• Oncologia Ospedale Civile, Saluzzo (Cuneo): Davide Perroni, Ivan 
Facilissimo, Lucia Evangelisti 
• S.C. Oncologia Ospedale Santa Maria degli Angeli, Pordenone: Alesssandro 
Del Conte, Antonino Ius 
• S.C. Oncologia Ospedale Regionale U.Parini, Aosta: Gianmauro Numico, 
Antonella Cristofano, Cristina Barè 
• Oncologia Ospedale del Delta, Lagosanto (Ferrara): Pierluigi Ballardini, 
Guido Margutti 
• U.O. Oncologia Medica  Azienda Ospedaliera di Parma, Parma: Marcello 
Tiseo, Roberta Camisa, Elena Rapacchi, Marco Bartolotti 
• U.O. Oncologia Medica Ospedale San Gerardo, Monza (Monza e Brianza): 
Diego Cortinovis, Monica Perez Gila 
• S.S. Tumori Polmonari IST Istituto nazionale per la ricerca sul cancro, 
Genova: Francesco Grossi, Caterina Donato, Maria Giovanna Dal Bello, 
Erika Rijavec, Giulia Barletta, Carlo Genova, Nidia Diaz, Claudio Sini 
• Oncologia Medica Arcispedale S. Maria Nuova, Reggio Emilia: Corrado Boni, 
Francesca Zanelli, Roberta Gnoni, Giovanna Stridi, Elena Magnani, Erika 
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Gervasi, Silvia Fanello 
• Oncologia Ospedale di Romano Lombardia, Romano Lombardia (Bergamo): 
Veronica Lonati, Fausto Petrelli, Marco Cremonesi 
• S.C. Oncologia Azienda Ospedaliera Universitaria, Trieste: Guido Del Conte, 
Angela Dicorato 
• Oncologia Medica Ospedale Santa Chiara, Trento: Orazio Caffo, Viviana 
Murgia, Antonello Veccia 
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Figure legends 
Figure 1.  Histology at diagnosis by stage 
Figure 2. First-line treatment (for Stage IIIB and IV patients) 
 
